Autism spectrum disorders are increasingly understood to have a genetic component, but with the number of genes that could be involved in the disorder, developing a treatment is challenging. However, for autism associated with Phelan-McDermid syndrome—understood to be caused by a single nonfunctional or missing SHANK3 gene—a new gene therapy offers promise for targeting and restoring the gene, and Mount Sinai researchers leading findings in the clinical trial.